Moloney Securities Asset Management LLC acquired a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH – Free Report) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 18,800 shares of the company’s stock, valued at approximately $1,089,000.
Several other institutional investors and hedge funds have also bought and sold shares of the company. QRG Capital Management Inc. bought a new position in shares of Astrana Health in the third quarter worth $355,000. F M Investments LLC bought a new position in shares of Astrana Health in the third quarter worth $11,738,000. SteelPeak Wealth LLC bought a new position in shares of Astrana Health in the third quarter worth $39,398,000. New York State Teachers Retirement System bought a new position in shares of Astrana Health in the third quarter worth $2,515,000. Finally, Nisa Investment Advisors LLC bought a new position in shares of Astrana Health in the third quarter worth $35,000. 52.77% of the stock is owned by institutional investors.
Astrana Health Price Performance
NASDAQ:ASTH opened at $56.00 on Wednesday. The stock has a fifty day moving average of $55.07 and a 200 day moving average of $47.23. Astrana Health, Inc. has a 52-week low of $28.86 and a 52-week high of $63.20. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of 38.89, a P/E/G ratio of 2.08 and a beta of 1.24.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on ASTH. TD Cowen began coverage on Astrana Health in a report on Monday, October 14th. They issued a “buy” rating and a $66.00 price target for the company. KeyCorp initiated coverage on Astrana Health in a report on Friday, October 11th. They issued a “sector weight” rating for the company. BTIG Research lifted their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Robert W. Baird lifted their price objective on Astrana Health from $54.00 to $67.00 and gave the company an “outperform” rating in a research note on Thursday, August 15th. Finally, Stifel Nicolaus lifted their price objective on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Astrana Health currently has an average rating of “Buy” and a consensus price target of $62.00.
View Our Latest Analysis on Astrana Health
Astrana Health Company Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
See Also
- Five stocks we like better than Astrana Health
- Dividend Payout Ratio Calculator
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Trading Stocks: RSI and Why it’s Useful
- Insider Buying Signals Upside for These 3 Stocks
- Election Stocks: How Elections Affect the Stock Market
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH – Free Report).
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.